Role of IL-21 in immune-regulation and tumor immunotherapy

Emma Di Carlo, Daniela De Totero, Tiziana Piazza, Marina Fabbi, Silvano Ferrini

Research output: Contribution to journalArticle

Abstract

IL-21, the most recently discovered member of the IL-2 cytokine family, is an attractive subject for research due to its involvement in experimental models of autoimmunity, its ability to down-regulate IgE production, and its anti-tumor properties. Its interest for cancer immunotherapy stems from its physiological immune-enhancing functions. These include regulation of T, B and NK cell proliferation, survival, differentiation, and effector functions. IL-21's functional activities partially overlap those of IL-2. Both cytokines display similar structural features and use the common γ-chain receptor and its downstream signaling pathways. Besides its activities on normal lymphoid cells, IL-21 is an in vitro growth factor for myeloma and acute-T cell leukemia cells, whereas it induces the apoptosis of B-CLL (chronic lymphocytic leukemia) cells. These findings indicate that the IL-21/IL-21R system exerts opposite functions in different lymphoid neoplasias, and suggest its employment in B-CLL therapy. Since IL-2, but not IL-21, is specifically required for the development of regulatory T (Treg) cell immune-suppressive functions, IL-21 may be a new tool for cancer immunotherapy. It is, in fact, a powerful anti-tumor agent in a variety of murine experimental tumor models through its activation of specific or innate immune responses against neoplastic cells. The preliminary data from phase-I clinical studies suggest that the use of IL-21 is feasible and may result in immune-enhancing effects.

Original languageEnglish
Pages (from-to)1323-1334
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume56
Issue number9
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Immunotherapy
Neoplasms
Interleukin-2
Regulatory T-Lymphocytes
Theoretical Models
Cytokines
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia
interleukin-21
Autoimmunity
Innate Immunity
Natural Killer Cells
Immunoglobulin E
Cell Survival
Intercellular Signaling Peptides and Proteins
B-Lymphocytes
Down-Regulation
Cell Proliferation
Lymphocytes
Apoptosis

Keywords

  • Immune-regulation
  • Interleukin-21
  • Lymphoid neoplasia
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Role of IL-21 in immune-regulation and tumor immunotherapy. / Di Carlo, Emma; De Totero, Daniela; Piazza, Tiziana; Fabbi, Marina; Ferrini, Silvano.

In: Cancer Immunology, Immunotherapy, Vol. 56, No. 9, 07.2007, p. 1323-1334.

Research output: Contribution to journalArticle

Di Carlo, Emma ; De Totero, Daniela ; Piazza, Tiziana ; Fabbi, Marina ; Ferrini, Silvano. / Role of IL-21 in immune-regulation and tumor immunotherapy. In: Cancer Immunology, Immunotherapy. 2007 ; Vol. 56, No. 9. pp. 1323-1334.
@article{69c718e029be43d998443e33dddd487e,
title = "Role of IL-21 in immune-regulation and tumor immunotherapy",
abstract = "IL-21, the most recently discovered member of the IL-2 cytokine family, is an attractive subject for research due to its involvement in experimental models of autoimmunity, its ability to down-regulate IgE production, and its anti-tumor properties. Its interest for cancer immunotherapy stems from its physiological immune-enhancing functions. These include regulation of T, B and NK cell proliferation, survival, differentiation, and effector functions. IL-21's functional activities partially overlap those of IL-2. Both cytokines display similar structural features and use the common γ-chain receptor and its downstream signaling pathways. Besides its activities on normal lymphoid cells, IL-21 is an in vitro growth factor for myeloma and acute-T cell leukemia cells, whereas it induces the apoptosis of B-CLL (chronic lymphocytic leukemia) cells. These findings indicate that the IL-21/IL-21R system exerts opposite functions in different lymphoid neoplasias, and suggest its employment in B-CLL therapy. Since IL-2, but not IL-21, is specifically required for the development of regulatory T (Treg) cell immune-suppressive functions, IL-21 may be a new tool for cancer immunotherapy. It is, in fact, a powerful anti-tumor agent in a variety of murine experimental tumor models through its activation of specific or innate immune responses against neoplastic cells. The preliminary data from phase-I clinical studies suggest that the use of IL-21 is feasible and may result in immune-enhancing effects.",
keywords = "Immune-regulation, Interleukin-21, Lymphoid neoplasia, Tumor immunotherapy",
author = "{Di Carlo}, Emma and {De Totero}, Daniela and Tiziana Piazza and Marina Fabbi and Silvano Ferrini",
year = "2007",
month = "7",
doi = "10.1007/s00262-007-0326-z",
language = "English",
volume = "56",
pages = "1323--1334",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "9",

}

TY - JOUR

T1 - Role of IL-21 in immune-regulation and tumor immunotherapy

AU - Di Carlo, Emma

AU - De Totero, Daniela

AU - Piazza, Tiziana

AU - Fabbi, Marina

AU - Ferrini, Silvano

PY - 2007/7

Y1 - 2007/7

N2 - IL-21, the most recently discovered member of the IL-2 cytokine family, is an attractive subject for research due to its involvement in experimental models of autoimmunity, its ability to down-regulate IgE production, and its anti-tumor properties. Its interest for cancer immunotherapy stems from its physiological immune-enhancing functions. These include regulation of T, B and NK cell proliferation, survival, differentiation, and effector functions. IL-21's functional activities partially overlap those of IL-2. Both cytokines display similar structural features and use the common γ-chain receptor and its downstream signaling pathways. Besides its activities on normal lymphoid cells, IL-21 is an in vitro growth factor for myeloma and acute-T cell leukemia cells, whereas it induces the apoptosis of B-CLL (chronic lymphocytic leukemia) cells. These findings indicate that the IL-21/IL-21R system exerts opposite functions in different lymphoid neoplasias, and suggest its employment in B-CLL therapy. Since IL-2, but not IL-21, is specifically required for the development of regulatory T (Treg) cell immune-suppressive functions, IL-21 may be a new tool for cancer immunotherapy. It is, in fact, a powerful anti-tumor agent in a variety of murine experimental tumor models through its activation of specific or innate immune responses against neoplastic cells. The preliminary data from phase-I clinical studies suggest that the use of IL-21 is feasible and may result in immune-enhancing effects.

AB - IL-21, the most recently discovered member of the IL-2 cytokine family, is an attractive subject for research due to its involvement in experimental models of autoimmunity, its ability to down-regulate IgE production, and its anti-tumor properties. Its interest for cancer immunotherapy stems from its physiological immune-enhancing functions. These include regulation of T, B and NK cell proliferation, survival, differentiation, and effector functions. IL-21's functional activities partially overlap those of IL-2. Both cytokines display similar structural features and use the common γ-chain receptor and its downstream signaling pathways. Besides its activities on normal lymphoid cells, IL-21 is an in vitro growth factor for myeloma and acute-T cell leukemia cells, whereas it induces the apoptosis of B-CLL (chronic lymphocytic leukemia) cells. These findings indicate that the IL-21/IL-21R system exerts opposite functions in different lymphoid neoplasias, and suggest its employment in B-CLL therapy. Since IL-2, but not IL-21, is specifically required for the development of regulatory T (Treg) cell immune-suppressive functions, IL-21 may be a new tool for cancer immunotherapy. It is, in fact, a powerful anti-tumor agent in a variety of murine experimental tumor models through its activation of specific or innate immune responses against neoplastic cells. The preliminary data from phase-I clinical studies suggest that the use of IL-21 is feasible and may result in immune-enhancing effects.

KW - Immune-regulation

KW - Interleukin-21

KW - Lymphoid neoplasia

KW - Tumor immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=34347368503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347368503&partnerID=8YFLogxK

U2 - 10.1007/s00262-007-0326-z

DO - 10.1007/s00262-007-0326-z

M3 - Article

C2 - 17447063

AN - SCOPUS:34347368503

VL - 56

SP - 1323

EP - 1334

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 9

ER -